VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

被引：43
|
作者：
Carbone, David P. [1 ]
Salmon, J. Stuart [3 ]
Billheimer, Dean [2 ]
Chen, Heidi [1 ]
Sandler, Alan [1 ]
Roder, Heinrich [4 ]
Roder, Joanna [4 ]
Tsypin, Maxim
Herbst, Roy S. [5 ]
Tsao, Anne S. [5 ]
Tran, Hai T. [5 ]
Dang, Thao P. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Carolinas Hematol Oncol Associates, Charlotte, NC USA
[4] Biodesix, Steamboat Springs, CO USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LUNG CANCER | 2010年 / 69卷 / 03期
关键词：
Lung cancer; Erlotinib; Bevacizumab; Serum biomarker; Proteomics; Personalized therapy; ENDOTHELIAL GROWTH-FACTOR; MASS-SPECTROMETRY; CHEMOTHERAPY; COMBINATION; RECURRENT;
D O I：
10.1016/j.lungcan.2009.11.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat (R)) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat (R) could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：337 / 340
页数：4
相关论文
共 50 条
  • [11] Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)
    Cedres Perez, S.
    Prat, A.
    Felip, E.
    Peralta, S.
    Perez, J.
    del Campo, J.
    Sala, G.
    Andreu, J.
    Pallisa, E.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [12] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [13] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Hudoyo, Ahmad
    Andarini, Sita
    RESPIROLOGY, 2015, 20 : 101 - 101
  • [14] Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of non-small cell lung cancer patients treated with erlotinib
    Lazzari, Chiara
    Tiseo, Marcello
    Gregorc, Vanesa
    Latteri, Fiorenza
    Ippolito, Massimo
    Balderi, Segio
    Cosentino, Sebastiano
    Scarlattei, Maura
    Roder, Heinrich
    Grigorieva, Julia
    Roder, Joanna
    Bordonaro, Roberto
    Ardizzoni, Andrea
    Gianni, Luca
    Parra, Hector J. Soto
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [15] High-throughput detection of alternative splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib
    Baty, Florent
    Brutsche, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [16] High-Throughput Alternative Splicing Detection In Patients With Non-Small Cell Lung Cancer Treated By Bevacizumab/erlotinib
    Baty, F.
    Brutsche, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [17] Wood-Smoke Exposure (WSE) as a Predictor of Response and Survival in Erlotinib-Treated Non-small Cell Lung Cancer (NSCLC) Patients
    Cardona, Andres Felipe
    Reguart, Noemi
    Reveiz, Ludovic
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) : 142 - 143
  • [18] Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib
    Cedres, Susana
    Prat, Aleix
    Martinez, Pablo
    Pallisa, Esther
    Sala, Gemma
    Andreu, Jordi
    del Campo, J. M.
    Quispe, Isela
    Baselga, Jose
    Felip, Enriqueta
    LUNG CANCER, 2009, 66 (02) : 257 - 261
  • [19] Combination of erlotinib and bevacizumab in non small cell lung cancer patients
    Boutsikou, Efimia
    Kontakiotis, Theodoros
    Zarogoulidis, Pavlos
    Pataka, Paraskevi
    Zarogoulidis, Kostas
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [20] Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer
    Chikaishi, Yasuhiro
    Kanayama, Masatoshi
    Taira, Akihiro
    Nabe, Yusuke
    Shinohara, Shinji
    Kuwata, Taiji
    Takenaka, Masaru
    Oka, Soichi
    Hirai, Ayako
    Kuroda, Koji
    Imanishi, Naoko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (20)
12345